Ischemic stroke occurs when a blood vessel supplying the brain is obstructed.
Consider stroke in any patient presenting with sudden focal neurological deficit or any alteration in level of consciousness.
Rapid evaluation is essential for sure of time-sensitive treatments.
Determine if patient's symptoms are due to stroke and exclude stroke mimics (eg migraine, hypertensive encephalopathy, hypoglycemia, seizures or post-ictal paresis); identify other conditions requiring immediate intervention and determine the potential causes of stroke.
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
A novel, noninvasive wearable brain stimulation device that delivers continuous transcranial magnetic stimulation to induce the brain to rewire itself significantly increases brain activity and is safe in patients with chronic ischaemic stroke — thus presenting a step forward to improving motor function after stroke, suggests a preliminary study presented at ISC 2020 Meeting.
A multicenter trial to investigate whether antithrombotic therapy can be initiated in atrial fibrillation (AF) patients who have survived an intracerebral haemorrhage (ICH) can be done, based on the results of the phase II feasibility trial NASPAF-ICH* presented at the 2020 International Stroke Conference (ISC).
Being male and having a high genetic predisposition to sustain an acute vascular event (AVE) predict greater risks of stroke and myocardial infarction (MI) than either factor does alone in a population of middle-aged individuals without vascular risk factors, as shown in a study presented at the International Stroke Conference (ISC) 2020.
Patients with atherosclerotic disease who have had an ischaemic stroke or transient ischaemic attack (TIA) may fare better with a lower low-density lipoprotein cholesterol (LDL-C) target, as reducing LDL-C levels even below the 90–110 mg/dL target range at <70 mg/dL confers superior protection against the risk of subsequent stroke, according to data from the Treat Stroke to Target trial.
The timing of direct oral anticoagulants (DOACs) administration, either within 3 days or ≥4 days of stroke onset, in patients with nonvalvular atrial fibrillation (AF) does not alter the risk of adverse outcomes such as stroke or systemic embolism, major bleeding, and death, as shown in a recent study.
Asian ischaemic stroke patients with small and fragile cerebral vessels, as evidenced by the presence of multiple cerebral microbleeds (CMBs), may fare better with cilostazol than aspirin, as the former proves more effective at preventing cerebral haemorrhages especially when administered before white matter changes become extensive, according to the results of a subgroup analysis of the PICASSO* trial.
The mean heart rate during acute stroke period factors in mortality but not stroke recurrence in patients with atrial fibrillation hospitalized for acute ischaemic stroke, a study has found. Heart rate variability has no effect on both outcomes.
A gout drug that’s been around for years reduced the risk of ischaemic cardiovascular (CV) events when given at a low dose in patients who had myocardial infarction (MI) and was cost-effective, an analysis of the COLCOT* trial has shown.
Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.